Regulation of cellular iron metabolism and its implications in lung cancer progression

Medical Oncology

Volumn 31, Issue 7, 2014, Pages

  Xiong, Wei ^a   Wang, Li ^a   Yu, Fenglei ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Bone morphogenetic proteins; Ferritin; Ferroportin; Hepcidin; Iron; Lung cancer

Indexed keywords

BONE MORPHOGENETIC PROTEIN; HEPCIDIN; IRON;

ANTIPROLIFERATIVE ACTIVITY; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; DISEASE ASSOCIATION; EFFUSION; HUMAN; IRON BALANCE; IRON EFFLUX; IRON METABOLISM; IRON OVERLOAD; IRON STORAGE; IRON TRANSPORT; LUNG CANCER; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY;

BONE MORPHOGENETIC PROTEINS; GENE EXPRESSION REGULATION; HEPCIDINS; HUMANS; IRON; IRON OVERLOAD; LUNG NEOPLASMS;

EID: 84901584147     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0028-2     Document Type: Review

References (75)

1. Tandon M, Gokul K, Ali SA, et al. Runx2 mediates epigenetic silencing of the bone morphogenetic protein-3B (BMP-3B/GDF10) in lung cancer cells. Mol Cancer. 2012;11:27.
2. Ridge CA, McErlean AM, Ginsberg MS. Epidemiology of lung cancer. Semin Intervent Radiol. 2013;30:93-8.
3. Fuster LM, Sandler AB. Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes. Clin Lung Cancer. 2004;6(Suppl 1):S24-9.
4. Vijayalakshmi R, Krishnamurthy A. Targetable, "driver" mutations in non small cell lung cancer. Indian J Surg Oncol. 2011;2:178-88.
5. Domvri K, Zarogoulidis P, Darwiche K, et al. Molecular targeted drugs and biomarkers in NSCLC, the evolving role of individualized therapy. J Cancer. 2013;4:736-54.
6. Wang SJ, Gao C, Chen BA. Advancement of the study on iron metabolism and regulation in tumor cells. Chin J Cancer. 2010;29:451-5.
7. Kabat GC, Rohan TE. Does excess iron play a role in breast carcinogenesis? An unresolved hypothesis. Cancer Causes Control. 2007;18:1047-53. (Pubitemid 47498168)
8. Torti SV, Torti FM. Cellular iron metabolism in prognosis and therapy of breast cancer. Crit Rev Oncog. 2013;18:435-48.
9. Wild P, Bourgkard E, Paris C. Lung cancer and exposure to metals: the epidemiological evidence. Methods Mol Biol. 2009;472:139-67.
10. Palmer S. Diet, nutrition, and cancer. Prog Food Nutr Sci. 1985;9:283-341.
11. Steegmann-Olmedillas JL. The role of iron in tumour cell proliferation. Clin Transl Oncol. 2011;13:71-6.
12. Yu Y, Gutierrez E, Kovacevic Z, et al. Iron chelators for the treatment of cancer. Curr Med Chem. 2012;19:2689-702.
13. Yu Y, Suryo Rahmanto Y, Richardson DR. Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy. Br J Pharmacol. 2012;165:148-66.
14. Andrews NC. Understanding heme transport. N Engl J Med. 2005;353:2508-9. (Pubitemid 41770172)
15. Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer. 2013;13:342-55.
16. Kukulj S, Jaganjac M, Boranic M, Krizanac S, Santic Z, Poljak-Blazi M. Altered iron metabolism, inflammation, transferrin receptors, and ferritin expression in non-small-cell lung cancer. Med Oncol. 2010;27:268-77.
17. Alemán MR, Santolaria F, Batista N, et al. Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition? Cytokine. 2002;19:21-6.
18. Yildirim A, Meral M, Kaynar H, Polat H, Ucar EY. Relationship between serum levels of some acute-phase proteins and stage of disease and performance status in patients with lung cancer. Med Sci Monit. 2007;13:CR195-200. (Pubitemid 46557755)
19. Niklinski J, Furman M. Clinical tumour markers in lung cancer. Eur J Cancer Prev. 1995;4:129-38.
20. Akerstrom B, Flower DR, Salier JP. Lipocalins: unity in diversity. Biochim Biophys Acta. 2000;1482:1-8.
21. Devireddy LR, Gazin C, Zhu X, Green MR. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell. 2005;123:1293-305. (Pubitemid 41821786)
22. Devireddy LR, Hart DO, Goetz DH, Green MR. A mammalian siderophore synthesized by an enzyme with a bacterial homolog involved in enterobactin production. Cell. 2010;141:1006-17.
23. Shiiba M, Saito K, Fushimi K, et al. Lipocalin-2 is associated with radioresistance in oral cancer and lung cancer cells. Int J Oncol. 2013;42:1197-204.
24. Wu MF, Hsiao YM, Huang CF, et al. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells. J Thorac Oncol. 2010;5:1143-51.
25. Hanai J, Mammoto T, Seth P, et al. Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells. J Biol Chem. 2005;280:13641-7. (Pubitemid 40517258)
26. Kakhlon O, Gruenbaum Y, Cabantchik ZI. Ferritin expression modulates cell cycle dynamics and cell responsiveness to H-ras-induced growth via expansion of the labile iron pool. Biochem J. 2002;363:431-6. (Pubitemid 34526363)
27. Milman N, Pedersen LM. The serum ferritin concentration is a significant prognostic indicator of survival in primary lung cancer. Oncol Rep. 2002;9:193-8.
28. Koc M, Taysi S, Sezen O, Bakan N. Levels of some acute-phase proteins in the serum of patients with cancer during radiotherapy. Biol Pharm Bull. 2003;26:1494-7. (Pubitemid 41685407)
29. Zhang F, Wang W, Tsuji Y, Torti SV, Torti FM. Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest. J Biol Chem. 2008;283:33911-8.
30. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem. 2000;275:19906-12. (Pubitemid 30441595)
31. Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med. 2011;62:347-60.
32. Ganz T, Nemeth E. The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematol Am Soc Hematol Educ Progr. 2011;2011:538-42.
33. Pinnix ZK, Miller LD, Wang W, et al. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med. 2010;2:43ra56.
34. Wang Q, Zhou J, Zhong D, Wang Q, Huang J. Ferroportin in the progression and prognosis of hepatocellular carcinoma. Eur J Med Res. 2013;18:59.
35. Pogribny IP. Ferroportin and hepcidin: a new hope in diagnosis, prognosis, and therapy for breast cancer. Breast Cancer Res. 2010;12:314.
36. Brookes MJ, Hughes S, Turner FE, et al. Modulation of iron transport proteins in human colorectal carcinogenesis. Gut. 2006;55:1449-60. (Pubitemid 44476791)
37. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090-3. (Pubitemid 40007660)
38. Vokurka M, Krijt J, Vávrová J, Nečas E. Hepcidin expression in the liver of mice with implanted tumour reacts to iron deficiency, inflammation and erythropoietin administration. Folia Biol (Praha). 2011;57:248-54.
39. Schmidt PJ, Toran PT, Giannetti AM, Bjorkman PJ, Andrews NC. The transferrin receptor modulates Hfe-dependent regulation of hepcidin expression. Cell Metab. 2008;7:205-14. (Pubitemid 351285524)
40. Gao J, Chen J, Kramer M, Tsukamoto H, Zhang AS, Enns CA. Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression. Cell Metab. 2009;9:217-27.
41. Ramey G, Deschemin JC, Vaulont S. Cross-talk between the mitogen activated protein kinase and bone morphogenetic protein/hemojuvelin pathways is required for the induction of hepcidin by holotransferrin in primary mouse hepatocytes. Haematologica. 2009;94:765-72.
42. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood. 2006;108:3204-9.
43. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008;112:4292-7.
44. Bartnikas TB, Andrews NC, Fleming MD. Transferrin is a major determinant of hepcidin expression in hypotransferrinemic mice. Blood. 2011;117:630-7.
45. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood. 2006;108:3730-5. (Pubitemid 44864551)
46. Kamai T, Tomosugi N, Abe H, Arai K, Yoshida K. Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma. BMC Cancer. 2009;9:270.
47. Kijima H, Sawada T, Tomosugi N, Kubota K. Expression of hepcidin mRNA is uniformly suppressed in hepatocellular carcinoma. BMC Cancer. 2008;8:167.
48. Ward DG, Roberts K, Stonelake P, et al. SELDI-TOF-MS determination of hepcidin in clinical samples using stable isotope labelled hepcidin as an internal standard. Proteome Sci. 2008;6:28.
49. Rivera S, Liu L, Nemeth E, Gabayan V, Sorensen OE, Ganz T. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood. 2005;105:1797-802. (Pubitemid 40223704)
50. Chen Q, Wang L, Ma Y, Wu X, Jin L, Yu F. Increased hepcidin expression in non-small cell lung cancer tissue and serum is associated with clinical stage. Thorac Cancer. 2014;5:14-24.
51. Lien SC, Chang SF, Lee PL, et al. Mechanical regulation of cancer cell apoptosis and autophagy: roles of bone morphogenetic protein receptor, Smad1/5, and p38 MAPK. Biochim Biophys Acta. 2013;1833:3124-33.
52. Langenfeld E, Hong CC, Lanke G, Langenfeld J. Bone morphogenetic protein type I receptor antagonists decrease growth and induce cell death of lung cancer cell lines. PLoS ONE. 2013;8:e61256.
53. Miyazono K, Kamiya Y, Morikawa M. Bone morphogenetic protein receptors and signal transduction. J Biochem. 2010;147:35-51.
54. Choi YJ, Kim ST, Park KH, et al. The serum bone morphogenetic protein-2 level in non-small-cell lung cancer patients. Med Oncol. 2012;29:582-8.
55. Nickel J, Sebald W, Groppe JC, Mueller TD. Intricacies of BMP receptor assembly. Cytokine Growth Factor Rev. 2009;20:367-77.
56. Hsu YL, Huang MS, Yang CJ, Hung JY, Wu LY, Kuo PL. Lung tumor-associated osteoblast-derived bone morphogenetic protein-2 increased epithelial-to- mesenchymal transition of cancer by Runx2/Snail signaling pathway. J Biol Chem. 2011;286:37335-46.
57. Babitt JL, Huang FW, Wrighting DM, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet. 2006;38:531-9.
58. Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet. 2004;36:77-82. (Pubitemid 38056211)
59. Lin L, Nemeth E, Goodnough JB, Thapa DR, Gabayan V, Ganz T. Soluble hemojuvelin is released by proprotein convertase-mediated cleavage at a conserved polybasic RNRR site. Blood Cells Mol Dis. 2008;40:122-31. (Pubitemid 350193320)
60. Perry MJ, McDougall KE, Hou SC, Tobias JH. Impaired growth plate function in bmp-6 null mice. Bone. 2008;42:216-25. (Pubitemid 350297190)
61. Niederkofler V, Salie R, Arber S. Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. J Clin Invest. 2005;115:2180-6. (Pubitemid 41134159)
62. Ramos E, Kautz L, Rodriguez R, et al. Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice. Hepatology. 2011;53:1333-41.
63. Xia Y, Babitt JL, Sidis Y, Chung RT, Lin HY. Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood. 2008;111:5195-204.
64. Zhang AS, Anderson SA, Wang J, et al. Suppression of hepatic hepcidin expression in response to acute iron deprivation is associated with an increase of matriptase-2 protein. Blood. 2011;117:1687-99.
65. Steinbicker AU, Bartnikas TB, Lohmeyer LK, et al. Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice. Blood. 2011;118:4224-30.
66. Salahudeen AA, Bruick RK. Maintaining mammalian iron and oxygen homeostasis: sensors, regulation, and cross-talk. Ann N Y Acad Sci. 2009;1177:30-8.
67. Le Page C, Puiffe ML, Meunier L, et al. BMP-2 signaling in ovarian cancer and its association with poor prognosis. J Ovarian Res. 2009;2:4.
68. Park Y, Kang MH, Seo HY, et al. Bone morphogenetic protein-2 levels are elevated in the patients with gastric cancer and correlate with disease progression. Med Oncol. 2010;27:1192-9.
69. Gupta GP, Perk J, Acharyya S, et al. ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci USA. 2007;104:19506-11.
70. Swarbrick A, Roy E, Allen T, Bishop JM. Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence response. Proc Natl Acad Sci USA. 2008;105:5402-7. (Pubitemid 351753875)
71. Langenfeld EM, Kong Y, Langenfeld J. Bone morphogenetic protein-2-induced transformation involves the activation of mammalian target of rapamycin. Mol Cancer Res. 2005;3:679-84. (Pubitemid 43042997)
72. Raida M, Clement JH, Leek RD, Ameri K, Bicknell R, Niederwieser D, Harris AL. Bone morphogenetic protein 2 (BMP-2) and induction of tumor angiogenesis. J Cancer Res Clin Oncol. 2005;131:741-50. (Pubitemid 41577951)
73. Rothhammer T, Bataille F, Spruss T, Eissner G, Bosserhoff AK. Functional implication of BMP4 expression on angiogenesis in malignant melanoma. Oncogene. 2007;26:4158-70. (Pubitemid 46920167)
74. Fang WT, Fan CC, Li SM, et al. Downregulation of a putative tumor suppressor BMP4 by SOX2 promotes growth of lung squamous cell carcinoma. Int J Cancer. 2014. doi:10.1002/ijc.28734.
75. Kraunz KS, Nelson HH, Liu M, Wiencke JK, Kelsey KT. Interaction between the bone morphogenetic proteins and Ras/MAPkinase signalling pathways in lung cancer. Br J Cancer. 2005;93:949-52. (Pubitemid 41487023)